Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis
Status:
Completed
Trial end date:
2018-05-02
Target enrollment:
Participant gender:
Summary
This study assessed the safety and pharmacokinetics (PK) of a single dose application of
ARQ-151 cream 0.5% to 25 cm^2 of psoriatic plaque(s) (Cohort 1). The study also assessed the
safety, PK and efficacy of ARQ-151 cream 0.5% vs vehicle and ARQ-151 cream 0.15% vs vehicle
applied once a day for 28 days to individuals with 0.5% to 5.0% body surface area (BSA) of
chronic plaque psoriasis (Cohort 2).